JP2016500251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500251A5 JP2016500251A5 JP2015545522A JP2015545522A JP2016500251A5 JP 2016500251 A5 JP2016500251 A5 JP 2016500251A5 JP 2015545522 A JP2015545522 A JP 2015545522A JP 2015545522 A JP2015545522 A JP 2015545522A JP 2016500251 A5 JP2016500251 A5 JP 2016500251A5
- Authority
- JP
- Japan
- Prior art keywords
- target
- cancer
- subject
- infectious agent
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012678 infectious agent Substances 0.000 claims 4
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000005457 optimization Methods 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732760P | 2012-12-03 | 2012-12-03 | |
| US61/732,760 | 2012-12-03 | ||
| US201361801187P | 2013-03-15 | 2013-03-15 | |
| US61/801,187 | 2013-03-15 | ||
| PCT/US2013/072918 WO2014089113A1 (en) | 2012-12-03 | 2013-12-03 | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002712A Division JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016500251A JP2016500251A (ja) | 2016-01-12 |
| JP2016500251A5 true JP2016500251A5 (enExample) | 2017-01-19 |
Family
ID=49877017
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545522A Pending JP2016500251A (ja) | 2012-12-03 | 2013-12-03 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2019002712A Active JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2021065226A Pending JP2021113197A (ja) | 2012-12-03 | 2021-04-07 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2023045137A Pending JP2023078356A (ja) | 2012-12-03 | 2023-03-22 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002712A Active JP7132858B2 (ja) | 2012-12-03 | 2019-01-10 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2021065226A Pending JP2021113197A (ja) | 2012-12-03 | 2021-04-07 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
| JP2023045137A Pending JP2023078356A (ja) | 2012-12-03 | 2023-03-22 | 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20150322119A1 (enExample) |
| EP (2) | EP2925350B1 (enExample) |
| JP (4) | JP2016500251A (enExample) |
| CN (2) | CN104968364A (enExample) |
| CY (1) | CY1121557T1 (enExample) |
| DK (1) | DK2925350T3 (enExample) |
| ES (1) | ES2715673T3 (enExample) |
| HR (1) | HRP20190574T1 (enExample) |
| HU (1) | HUE043903T2 (enExample) |
| LT (1) | LT2925350T (enExample) |
| PL (1) | PL2925350T3 (enExample) |
| PT (1) | PT2925350T (enExample) |
| RS (1) | RS58528B1 (enExample) |
| SI (1) | SI2925350T1 (enExample) |
| SM (1) | SMT201900242T1 (enExample) |
| WO (1) | WO2014089113A1 (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277532A1 (en) | 2002-09-11 | 2011-01-26 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| WO2009126688A2 (en) | 2008-04-09 | 2009-10-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| KR20170017916A (ko) | 2014-05-13 | 2017-02-15 | 추가이 세이야쿠 가부시키가이샤 | 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자 |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| MX2016017288A (es) * | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| CA2957722C (en) | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2963974A1 (en) * | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| US10046047B2 (en) * | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| AU2016274585A1 (en) * | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
| EP3303397A1 (en) * | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| US20180179282A1 (en) | 2015-06-12 | 2018-06-28 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
| EP3325512B1 (en) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Multivalent and multispecific gitr-binding fusion proteins |
| EP3331917A1 (en) * | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| CN115925931A (zh) | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
| SG10202007764TA (en) | 2015-09-25 | 2020-09-29 | Genentech Inc | Anti-tigit antibodies and methods of use |
| PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| AU2016370648B2 (en) * | 2015-12-15 | 2023-03-09 | OncoC4, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| JP2019512271A (ja) | 2016-03-21 | 2019-05-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用 |
| WO2017177337A1 (en) * | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| SG11201808457PA (en) * | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| FR3051794A1 (fr) * | 2016-05-31 | 2017-12-01 | Lab Francais Du Fractionnement | Anticorps pour le traitement de cancers |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN110072890B (zh) * | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| SG11201907867TA (en) * | 2017-02-28 | 2019-09-27 | Bristol Myers Squibb Co | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019008375A1 (en) * | 2017-07-06 | 2019-01-10 | Ucl Business Plc | Method for identifying responders to cancer treatment |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN111051347B (zh) | 2017-09-29 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| TWI877769B (zh) | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| IT201800001315A1 (it) * | 2018-01-18 | 2019-07-18 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Nuovi agenti terapeutici antitumorali |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| KR102834864B1 (ko) * | 2018-02-02 | 2025-07-16 | 온코씨4, 아이앤씨. | 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체 |
| SG11202008593PA (en) | 2018-03-21 | 2020-10-29 | Five Prime Therapeutics Inc | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| BR112021000394A2 (pt) | 2018-07-12 | 2021-04-06 | F-Star Beta Limited | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| EP3841123A2 (en) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anti-tigit antibodies |
| TWI785268B (zh) * | 2018-08-29 | 2022-12-01 | 中央研究院 | 用於治療癌症的自然殺手細胞與環磷醯胺的組合 |
| US20210395392A1 (en) | 2018-10-09 | 2021-12-23 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| MA55316A (fr) | 2019-03-13 | 2022-01-19 | Merck Sharp & Dohme | Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 |
| CA3149719A1 (en) * | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| WO2021127554A1 (en) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| EP4119162A4 (en) | 2020-03-13 | 2023-08-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PVRIG-BINDING PROTEIN AND ITS MEDICAL USES |
| EP4136116A4 (en) | 2020-04-17 | 2024-06-19 | Hutchison Medipharma Limited | ANTI-OX40 ANTIBODIES AND USES THEREOF |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| US20230265192A1 (en) * | 2020-07-02 | 2023-08-24 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| CN116437926B (zh) | 2020-10-11 | 2026-01-20 | 百奥泰生物制药股份有限公司 | 抗pd-1抗体在联合用药中的应用 |
| US20240002513A1 (en) | 2020-11-06 | 2024-01-04 | Bristol-Myers Squibb Company | Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| US20240376207A1 (en) | 2021-09-15 | 2024-11-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
| JP2024535793A (ja) | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP4525991A1 (en) | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
| US20260048119A1 (en) | 2022-08-05 | 2026-02-19 | Bristol-Myers Squibb Company | Anti-ctla4 antibodies for treatment of kras mutant cancers |
| EP4681729A4 (en) | 2023-03-15 | 2026-07-15 | Shanghai Mabgen Biotech Ltd | PHARMACEUTICAL COMPOSITION CONTAINING A PD-1/PVRIG/TIGIT BINDING PROTEIN AND ITS MEDICAL USE |
| CN119219788A (zh) * | 2023-06-30 | 2024-12-31 | 凯米生物医药(成都)有限公司 | 经糖基修饰的融合蛋白、核酸分子、表达载体、宿主细胞及应用 |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2026096695A1 (en) | 2024-10-31 | 2026-05-07 | Bristol-Myers Squibb Company | Anti-fucosyl-gm1 antibody drug conjugates |
| US20260144884A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibody drug conjugates |
| US20260144885A1 (en) | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| DK1060247T3 (da) | 1998-02-24 | 2009-01-26 | Sisters Of Providence In Orego | Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CA2447695C (en) * | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| ES2295639T3 (es) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004215133B2 (en) * | 2003-02-27 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| CA2598454C (en) | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| ES2642787T3 (es) * | 2005-10-21 | 2017-11-20 | Lfb Usa, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| US7611702B2 (en) | 2005-11-08 | 2009-11-03 | Medarex, Inc. | TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| US20090175886A1 (en) | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| BRPI0811466A2 (pt) * | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| SI2242771T1 (sl) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| CN103597073B (zh) | 2011-03-06 | 2019-06-07 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
| BR112013021562B1 (pt) * | 2011-03-16 | 2023-01-10 | Argenx Bvba | Anticorpos para cd70 |
| WO2012149416A2 (en) * | 2011-04-28 | 2012-11-01 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| KR102119840B1 (ko) | 2011-07-11 | 2020-06-09 | 아이크노스 사이언스 에스. 아. | Ox40에 결합하는 항체 및 이들의 용도 |
| JP6038920B2 (ja) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| EP2817619B1 (en) * | 2012-02-23 | 2018-07-25 | Sloan Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
-
2013
- 2013-12-03 SM SM20190242T patent/SMT201900242T1/it unknown
- 2013-12-03 DK DK13811698.3T patent/DK2925350T3/da active
- 2013-12-03 PL PL13811698T patent/PL2925350T3/pl unknown
- 2013-12-03 PT PT13811698T patent/PT2925350T/pt unknown
- 2013-12-03 HR HRP20190574TT patent/HRP20190574T1/hr unknown
- 2013-12-03 ES ES13811698T patent/ES2715673T3/es active Active
- 2013-12-03 EP EP13811698.3A patent/EP2925350B1/en active Active
- 2013-12-03 CN CN201380072031.1A patent/CN104968364A/zh active Pending
- 2013-12-03 EP EP18209431.8A patent/EP3508215A3/en not_active Withdrawn
- 2013-12-03 HU HUE13811698A patent/HUE043903T2/hu unknown
- 2013-12-03 WO PCT/US2013/072918 patent/WO2014089113A1/en not_active Ceased
- 2013-12-03 SI SI201331367T patent/SI2925350T1/sl unknown
- 2013-12-03 RS RS20190387A patent/RS58528B1/sr unknown
- 2013-12-03 LT LTEP13811698.3T patent/LT2925350T/lt unknown
- 2013-12-03 CN CN202310218856.5A patent/CN116637183A/zh active Pending
- 2013-12-03 US US14/648,941 patent/US20150322119A1/en not_active Abandoned
- 2013-12-03 JP JP2015545522A patent/JP2016500251A/ja active Pending
-
2018
- 2018-02-13 US US15/895,655 patent/US20180312553A1/en not_active Abandoned
-
2019
- 2019-01-10 JP JP2019002712A patent/JP7132858B2/ja active Active
- 2019-04-16 CY CY20191100422T patent/CY1121557T1/el unknown
-
2020
- 2020-01-08 US US16/737,745 patent/US20200207816A1/en not_active Abandoned
-
2021
- 2021-04-07 JP JP2021065226A patent/JP2021113197A/ja active Pending
-
2023
- 2023-02-27 US US18/174,892 patent/US20230287064A1/en not_active Abandoned
- 2023-03-22 JP JP2023045137A patent/JP2023078356A/ja active Pending
-
2025
- 2025-01-17 US US19/030,567 patent/US20250236650A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515474A5 (enExample) | ||
| EP3508215A3 (en) | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| FI1897548T4 (fi) | T-solujen säätely | |
| WO2017132562A8 (en) | Antigen binding proteins that bind pd-l1 | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| JP2018514550A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| NZ604003A (en) | Monoclonal antibodies against her2 | |
| EP3421488A3 (en) | Multispecific antigen-binding molecules and uses thereof | |
| JP2013538057A5 (enExample) | ||
| UA114108C2 (uk) | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2015511962A5 (enExample) | ||
| WO2014055897A3 (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| EA201291243A1 (ru) | Антитела против респираторно-синцитиального вируса (рсв) и способы их применения | |
| JP2013231054A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| HK1208499A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| UA105760C2 (uk) | Антитіло проти bst2 | |
| WO2014012007A3 (en) | Rspo3 binding agents and uses thereof | |
| WO2016130539A3 (en) | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof | |
| WO2014007982A3 (en) | C-terminal and central epitope a-beta antibodies |